In particular, the timing of type I IFN-targeted treatment during radiotherapy should be carefully explored as it might induce beneficial and detrimental effects depending upon a delicate balance between responses within the tumor microenvironment, including but not restricted to STING signaling pathway capacity. Here, STING1 is linked to neoplasm.